Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilastatin versus placebo for nephroprotection during CRS+HIPEC with cisplatin
2022-001417-39Phase 2Active
- Sponsor
- Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of cilastatin in acute kidney failure (AKF) (2 arms), sponsored by Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón. Primary endpoint: Percentage of patients with renal failure at 7 days. Started Jan 2023; status: active.
02
Drugs
cilastatin
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on 2022-001417-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001417-39.